CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours

[1]  D. Speiser,et al.  CD4+ T cells in cancer , 2023, Nature Cancer.

[2]  D. Lambrechts,et al.  A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanoma , 2022, bioRxiv.

[3]  Aileen W. Li,et al.  A vaccine targeting resistant tumours by dual T cell plus NK cell attack , 2022, Nature.

[4]  Charles H. Yoon,et al.  Landscape of helper and regulatory antitumour CD4+ T cells in melanoma , 2022, Nature.

[5]  R. Gottardo,et al.  Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function. , 2022, Cancer cell.

[6]  Gregory M. Chen,et al.  Decade-long leukaemia remissions with persistence of CD4+ CAR T cells , 2022, Nature.

[7]  Si Ming Man,et al.  Interferon-γ primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway , 2022, Immunity.

[8]  Katie M. Campbell,et al.  Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma , 2021, Cancer discovery.

[9]  J. Zuber,et al.  Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumour microenvironment and cross-resistance to immunotherapy in melanoma , 2021, Nature Cancer.

[10]  K. Rock,et al.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation , 2021, Frontiers in Immunology.

[11]  C. Reis e Sousa,et al.  Dendritic Cells Revisited. , 2021, Annual review of immunology.

[12]  R. Webby,et al.  Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes , 2020, Cell.

[13]  T. Tüting,et al.  The aryl hydrocarbon receptor promotes inflammation‐induced dedifferentiation and systemic metastatic spread of melanoma cells , 2020, International journal of cancer.

[14]  Gregory F. Wu,et al.  cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity , 2020, Nature.

[15]  David R. Kelley,et al.  Solo: Doublet Identification in Single-Cell RNA-Seq via Semi-Supervised Deep Learning. , 2020, Cell systems.

[16]  Chun Jimmie Ye,et al.  Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer , 2020, Cell.

[17]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[18]  Johannes U. Mayer,et al.  Inflammatory Type 2 cDCs Acquire Features of cDC1s and Macrophages to Orchestrate Immunity to Respiratory Virus Infection , 2020, Immunity.

[19]  T. Schumacher,et al.  Long-distance modulation of bystander tumor cells by CD8+ T cell-secreted IFNγ , 2020, Nature Cancer.

[20]  A. Mantovani,et al.  Diversity, Mechanisms, and Significance of Macrophage Plasticity. , 2020, Annual review of pathology.

[21]  Graham M Lord,et al.  Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells , 2020, Immunity.

[22]  Fabian J Theis,et al.  Generalizing RNA velocity to transient cell states through dynamical modeling , 2019, Nature Biotechnology.

[23]  Josef Spidlen,et al.  Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets , 2019, Nature Communications.

[24]  Chun Jimmie Ye,et al.  Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity , 2019, Cell.

[25]  A. Butte,et al.  Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.

[26]  A. Mildner,et al.  Developmental and Functional Heterogeneity of Monocytes. , 2018, Immunity.

[27]  J. Borst,et al.  CD4+ T cell help in cancer immunology and immunotherapy , 2018, Nature Reviews Immunology.

[28]  B. Bogen,et al.  Tumor Killing by CD4+ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity , 2018, Front. Immunol..

[29]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[30]  Fabian J Theis,et al.  SCANPY: large-scale single-cell gene expression data analysis , 2018, Genome Biology.

[31]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[32]  Mario Faretta,et al.  Multiplex Staining by Sequential Immunostaining and Antibody Removal on Routine Tissue Sections , 2017, bioRxiv.

[33]  J. Aerts,et al.  SCENIC: Single-cell regulatory network inference and clustering , 2017, Nature Methods.

[34]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[35]  Chris Hinnah,et al.  Flat field correction for high‐throughput imaging of fluorescent samples , 2016, Journal of microscopy.

[36]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[37]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[38]  Jonathan L. Schmid-Burgk,et al.  OutKnocker: a web tool for rapid and simple genotyping of designer nuclease edited cell lines , 2014, Genome research.

[39]  D. Schadendorf,et al.  Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma , 2014, Nature.

[40]  L. Zender,et al.  T-helper-1-cell cytokines drive cancer into senescence , 2013, Nature.

[41]  J. Landsberg,et al.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.

[42]  P. Bousso,et al.  CD4+ T cells rely on a cytokine gradient to control intracellular pathogens beyond sites of antigen presentation. , 2012, Immunity.

[43]  B. Bonnotte,et al.  Th-1 Lymphocytes Induce Dendritic Cell Tumor Killing Activity by an IFN-γ–Dependent Mechanism , 2011, The Journal of Immunology.

[44]  R. Blasberg,et al.  Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts , 2010, The Journal of experimental medicine.

[45]  J. Landsberg,et al.  Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. , 2009, Cancer research.

[46]  P. Muranski,et al.  Tumor-specific Th17-polarized cells eradicate large established melanoma. , 2008, Blood.

[47]  Guttorm Haraldsen,et al.  Primary antitumor immune response mediated by CD4+ T cells. , 2005, Immunity.

[48]  Randall L. Lindquist,et al.  Visualizing dendritic cell networks in vivo , 2004, Nature Immunology.

[49]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[50]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[51]  Hao Shen,et al.  Cutting Edge: CD4 and CD8 T Cells Are Intrinsically Different in Their Proliferative Responses1 , 2002, The Journal of Immunology.

[52]  R. Schreiber,et al.  CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ , 1999 .

[53]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[54]  B. N. Chatterji,et al.  An FFT-based technique for translation, rotation, and scale-invariant image registration , 1996, IEEE Trans. Image Process..

[55]  R. Evans,et al.  Cooperation of Immune Lymphoid Cells with Macrophages in Tumour Immunity , 1970, Nature.

[56]  G. Mackaness.  THE IMMUNOLOGICAL BASIS OF ACQUIRED CELLULAR RESISTANCE , 1964, The Journal of experimental medicine.